Previous close | 334.02 |
Open | 334.02 |
Bid | 482.00 |
Ask | 491.00 |
Strike | 320.00 |
Expiry date | 2026-01-16 |
Day's range | 334.02 - 334.02 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Moody's released a new report Tuesday that reins in Wall Street expectations for the impact of GLP-1s on other industries.
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.